Major breakthrough in human autologous stem cells development

Source: Taiwan ASA Biotechnology Co. Ltd. ( Healthcare+ Expo- booth no.: L012)

The source of AMPC is human peripheral blood. 250 cc of whole blood is collected and processed in a blood machine to separate white blood cells. After 4 days of transformation, it becomes a pluripotent stem cell product. There is no proliferation during the process, and AMPC numbers is between 3-10 × 10^8. Its manufacturing process fully complies with the minimum operating standards of the US FDA and Australian TGA.

AMPC include hematopoietic stem cells, mesenchymal stem cells, endothelial stem cells, very small embryo-like stem cells, exosomes, platelet and variety of growth factors. AMPC has a homing effect, can endow stem cells with regenerative medical functions, and has great effects on the prevention and treatment of various diseases.

AMPC was approved by the Australian Health Authority (TGA) in February 2012 and can be used in clinical medical services, physicians directly perform autologous intravenous infusions. The medical procedures are covered by medical insurance of Lloyd's of London Insurance Company. So far May 2023, more than 2,000 AMPC autologous intravenous infusion cases have been completed, including kidney disease, cardiovascular disease, hepatobiliary and gastrointestinal diseases, leukemia, stroke, hormonal imbalance, male and female infertility, osteoarthritis, and joint degeneration , metabolic syndrome, neurological disorders, immune disorders, sexual dysfunction and other clinical diseases and medical aesthetics. All cases have no adverse reactions, are clinically safe, and have significant medical effects.